⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 30, 2024Open Access

Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy Mitesh J. Borad Rastilav Bahleda Cesar A. Perez Li‐Tzong Chen Shumei Kato Do‐Youn Oh Paul Severson Betty Y. Tam Cheng S. Quah James J. Harding

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 2 - Mean KIN-3248 Concentrations over time for Asian versus non-Asian Patients

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garmezy et al. (2024) studied this question.

synapsesocial.com/papers/68e6cd1ab6db64358764b66d https://doi.org/10.1158/2767-9764.25723496.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
2FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
3Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
4Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
5Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024

More related papers

Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024